The newly authorised drug, which treats probably deadly pulmonary arterial hypertension, is estimated to ring up as a lot as $7.5 billion in yearly gross sales.
The newly authorised drug, which treats probably deadly pulmonary arterial hypertension, is estimated to ring up as a lot as $7.5 billion in yearly gross sales.